Roxadustat effectiveness versus ESAs in peritoneal dialysis patients during the COVID-19 pandemic: A retrospective study
PLOS ONE · 2025
DOI: 10.1371/journal.pone.0320536 ↗Kurz gefasst
Vergleichsstudie in der Zeitschrift PLOS ONE, 2025. Verfasst von Jie Liu und 17 weiteren Autor:innen. Beteiligte Einrichtung: Department of Nephrology, The Second Affiliated Hospital of Xuzhou Medical University, Xuzhou , China. Hauptthemen laut MEDLINE: COVID-19, Peritoneal Dialysis, Hematinics, Anemia. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 35 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: the Science and technology development fund of Affiliated Hospital of Xuzhou Medical University, Xuzhou science and technology project.
Abstract (Originalsprache)
Background
The COVID-19 pandemic has made treating renal anemia in chronic kidney disease (CKD) patients undergoing peritoneal dialysis (PD) difficult. The current study aims to compare roxadustat with erythropoiesis-stimulating agents (ESAs) during the COVID-19 pandemic.
Methods
We conducted a single-center, retrospective study during the COVID-19 outbreak in China, from December 7, 2022, to January 31, 2023. The study involved patients undergoing PD who were divided based on the medication used to treat renal anemia; the roxadustat group (n = 34) and the ESAs group (n = 120). We analyzed the effectiveness of treating anemia, cost, medication adherence, and clinical outcomes related to COVID-19. Patients were followed up for 9 months.
Results
The baseline of hemoglobin levels was (110.03 ± 1.71 g/L in the roxadustat and 110.1 ± 1.52 g/L in the ESAs groups, respectively), after 9 months of inspections, the levels of hemoglobin were (121.26 ± 2.03 g/L in the roxadustat and 118.49 ± 1.35 g/L in the ESAs groups, respectively). The roxadustat subgroup analysis indicated that total cholesterol and low-density lipoprotein levels in the roxadustat group decreased from baseline in subjects not receiving statins (3.39 ± 0.12 vs. 4.2 ± 0.21 mmol/L and 2.21 ± 0.23 vs. 3.65 ± 0.37 mmol/L, P < 0.05 ). The Morisky score of the roxadustat group was higher [7 (5, 8) vs. 6 (4, 8), P < 0.01]. The drug cost of the roxadustat group was higher, but another additional cost for correcting anemia was significantly reduced. The infection rate of COVID-19 and the mortality rate caused by COVID-19 were lower in roxadustat group.
Conclusion
During the COVID-19 pandemic, both roxadustat and ESAs effectively improved renal anemia in PD patients, however, the roxadustat group experienced less additional costs for anemia correction and better medication compliance.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Nephrology, The Second Affiliated Hospital of Xuzhou Medical University, Xuzhou , China.
- Kangda College of Nanjing Medical University, Lianyungang, China.
- Department of Nephrology, Affiliated Hospital of Xuzhou Medical University, Xuzhou, China.
- Department of Nephrology, Beijing Aerospace General Hospital, Beijing, China.
- Department of Internal Medicine and Diagnostics, Xuzhou Medical University, Xuzhou, China.
ORCID-Profile: Xinglei Zhou
Förderung
- the Science and technology development fund of Affiliated Hospital of Xuzhou Medical University
- Xuzhou science and technology project
Zitieren
APA
Liu, J., Zhou, K., Meng, C., Liu, Z., Huang, R., Waheed, Y., Yang, F., Liu, K., Zhao, J., Zhang, L., Yu, X., Li, S., Li, T., Tong, Y., Wei, X., Tian, C., Sun, D., & Zhou, X. (2025). Roxadustat effectiveness versus ESAs in peritoneal dialysis patients during the COVID-19 pandemic: A retrospective study. PLOS ONE. https://doi.org/10.1371/journal.pone.0320536
Vancouver
Liu J, Zhou K, Meng C, Liu Z, Huang R, Waheed Y, et al. Roxadustat effectiveness versus ESAs in peritoneal dialysis patients during the COVID-19 pandemic: A retrospective study. PLOS ONE. 2025. doi:10.1371/journal.pone.0320536
BibTeX
@article{Liu2025,
author = {Liu, Jie and Zhou, Kefan and Meng, Chen and Liu, Zhuzhu and Huang, Ruihua and Waheed, Yousuf and Yang, Fan and Liu, Kun and Zhao, Jiaqi and Zhang, Lin and Yu, Xiaoyan and Li, Shuang and Li, Tianyu and Tong, Yanshan and Wei, Xiaodan and Tian, Chuankuo and Sun, Dong and Zhou, Xinglei},
title = {Roxadustat effectiveness versus ESAs in peritoneal dialysis patients during the COVID-19 pandemic: A retrospective study},
journal = {PLOS ONE},
year = {2025},
doi = {10.1371/journal.pone.0320536}
}
EUVIMED